RecruitingPhase 1NCT07241104
Cardiovascular
Dilated Cardiomyopathy
Also known as DCM, idiopathic dilated cardiomyopathy, familial DCM
Dilated Cardiomyopathy is characterised by dilation and impaired contractile function of the left or both ventricles, leading to heart failure, arrhythmia, and thromboembolic complications, and is the most common indication for cardiac tran
ORPHA:217604 ↗Gene LMNAGene MYH7Gene TTNGene SCN5A (multiple)Prevalence 1 per 250–2,500Onset Any age; most commonly adults aged 20–60Autosomal dominant (familial); also sporadic, X-linked, mitochondrial
57
studies recruiting now
as of 7 Sept 2026
304
studies registered in total
as of 7 Sept 2026
12
countries with a recruiting site
as of 7 Sept 2026
18 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07771465
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
RecruitingPhase 1 / Phase 2NCT07426419
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
RecruitingPhase 1 / Phase 2NCT07218887
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
RecruitingNCT07420907
Study of the Progression of Chronic Cardiovascular Conditions
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 57 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Dilated Cardiomyopathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: SHaRe Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Dilated Cardiomyopathy
Dilated Cardiomyopathy is characterised by dilation and impaired contractile function of the left or both ventricles, leading to heart failure, arrhythmia, and thromboembolic complications, and is the most common indication for cardiac transplantation. Genetic causes account for approximately 30–50% of cases, with pathogenic variants in TTN (titin) being the most frequent, followed by LMNA, MYH7, and SCN5A among many other genes. LMNA-related DCM carries a particularly severe prognosis due to its association with early and malignant arrhythmias and progressive conduction disease.
Common clinical features
Progressive breathlessness on exertion and at restPeripheral oedema and fluid retentionFatigue and reduced exercise capacityLeft ventricular ejection fraction below 45% on echocardiographyVentricular arrhythmias and palpitationsAtrioventricular conduction block (particularly in LMNA-DCM)Thromboembolic events including strokeCardiomegaly on chest radiograph
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
15 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Bromocriptine Mesylate (Bromocriptine mesylate)
Phase 3Ixmyelocel-T
Phase 3Enalaprilat (Enalaprilat)
Phase 3Perindopril
Phase 3Candesartan
Phase 3Arry-797
Phase 3Rosuvastatin
Phase 3Emprumapimod
+ 7 more in development
Before you apply
Things trial teams commonly ask about for Dilated Cardiomyopathy. Not eligibility rules; those are set by each study.
- Genetic testing identifying the causative gene (particularly LMNA) affects eligibility for gene-specific trials and risk stratification protocols; obtain panel results if available.
- Ejection fraction thresholds (e.g., LVEF below 35–45%) are standard inclusion criteria; ensure echocardiography or cardiac MRI has been performed within six months of screening.
- Stable optimised medical therapy (beta-blockers, ACE inhibitors/ARBs, SGLT2 inhibitors) is typically required before trial enrolment; document current medications carefully.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).